Evidence map›Paper›PMID 32125613›Full record

ArticleBrain imaging and behavior2021

Metabolic and amyloid PET network reorganization in Alzheimer's disease: differential patterns and partial volume effects.

Gabriel Gonzalez-Escamilla, Isabelle Miederer, Michel J Grothe, Mathias Schreckenberger, Muthuraman Muthuraman, Sergiu Groppa, Alzheimer’s Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Brain imaging and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gabriel Gonzalez-EscamillaDepartment of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany. ggonzale@uni-mainz.de.ORCID http://orcid.org/0000-0002-7209-1736
Isabelle MiedererDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Michel J GrotheGerman Center for Neurodegenerative Diseases (DZNE) - Rostock/Greifswald, Rostock, Germany.
Mathias SchreckenbergerDepartment of Nuclear Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Muthuraman MuthuramanDepartment of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
Sergiu GroppaDepartment of Neurology, Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Deutsche Forschungsgemeinschaft SFB-1193NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder, considered a disconnection syndrome with regional molecular pattern abnormalities quantifiable by the aid of PET imaging. Solutions for accurate quantification of network dysfunction are scarce. We evaluate the extent to which PET molecular markers reflect quantifiable network metrics derived through the graph theory framework and how partial volume effects (PVE)-correction (PVEc) affects these PET-derived metrics 75 AD patients and 126 cognitively normal older subjects (CN). Therefore our goal is twofold: 1) to evaluate the differential patterns of [

Indexed as

Alzheimer DiseaseAmyloidAniline CompoundsBrainFluorodeoxyglucose F18HumansMagnetic Resonance ImagingPositron-Emission TomographyAmyloidAniline CompoundsFluorodeoxyglucose F18Alzheimer’s diseaseBrain molecular networksMRIPartial volume effects correctionPET

Identifiers

PMID32125613
PMCPMC7835313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.